Predicta Biosciences is a precision oncology company focused on developing innovative diagnostic and therapeutic products. The company specializes in non-invasive diagnostics for blood cancers, particularly multiple myeloma, enabling physicians to assess the likelihood of patient response to immunotherapies. Founded by experts in cancer genomics, Predicta aims to address unmet needs in the diagnosis and prognosis of blood cancers and autoimmune diseases.